com uses cookies on this site. UN) today announces steps to strengthen its financial position, including financing and disposition initiatives, and a reduction to its monthly distribution. MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. -4. By continuing to use our service, you agree to our use of cookies. We also use them to share usage information with our partners. This news release constitutes a “designated news release” for the purposes of the. Investor Relations. MONTREAL, July 23, 2021 /CNW Telbec/ - Theratechnologies Inc. TH | March 7, 2023. 26, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the second quarter and first half of fiscal. Remember, high Theratechnologies' alpha is almost always a sign of. Theratechnologies is currently developing a platform of proprietary peptides called SORT1+ Technology TM for cancer drug development targeting SORT1. (2022-04-27 | TSX:TH) Theratechnologies to Focus Its Commercialization Activities on the North American Territory. a biopharmaceutical company focused on the development and commercialization of innovative therapies, today initiated enrollment of patients in the basket portion of the first-in-human study of TH1902, Theratechnologies’ investigational lead peptide drug conjugate (PDC) for the treatment of sortilin-expressing. MONTREAL, July 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 5000 0. 02, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. 617-356-1009. MONTREAL, Nov. R. Stockhouse. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. Approximately US$2,000,000, or CA$2,600,000, was paid in cash at closing. - On track to meet FY2022. We also use them to share. licensed the product from TaiMed Biologics, Inc. 4%. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its fourth quarter and full year fiscal 2022 ended November 30, on Tuesday, February 28, 2023. Trogarzo® and. Rosenberg, Reference is made to your letter dated August 16, 2012 regarding the Form 40-F for fiscal year-end November 30, 2011 filed by Theratechnologies Inc. - Q3 2022 North American Revenue Growth of 19%. MONTREAL, April 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 18% on the last trading day (Wednesday, 25th Oct 2023), rising from $1. Biopharmaceutical company Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. Theratechnologies, Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that new data featuring its investigational sortilin 1 (SORT1)-targeting peptide-drug conjugate technology will be presented in three posters at the American. MONTREAL, Sept. About TH1902. By continuing to use our service, you agree to our use of cookies. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic. Stockhouse. By continuing to use our service, you agree to our use of cookies. Theratechnologies had a negative net margin of 36. Proceeds to Be Used to Redeem All of the Outstanding 5. Cookies are used to. TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (Sort1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Sep 13. (THTX) Stock Price, Quote, latest community messages, chart, news and other stock related information. This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. 75. Small cap stock market news and analysis, portfolio tracking, investor message boards and forums (bullboards), newsletter aggregation and detailed snapshots of stock quotes for. 1. 3. Theratechnologies Appoints New Board Member. (TSX: TH) announced today that the Supreme Court of Canada has granted its appeal and dismissed 121851 Canada Inc. MONTREAL, Feb. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. com uses cookies on this site. 67% from the latest price. 9%, while the Biotechs industry saw earnings growing at 17. com. 63. $109. Headquartered in Montreal, Quebec (Canada), Theratechnologies commercializes two medicines in HIV and has research programs in HIV, NASH and Oncology. Theratechnologies to Announce Financial Results for Its First Quarter 2022. Stockhouse. Read More. In the United States, Trogarzo ® (ibalizumab. com uses cookies on this site. The SORT1 receptor plays a significant role in protein internalization, sorting and trafficking. (TSX: TH, Forum) noted that its Q1 2022 consolidated sales grew 20%, supported by 35% growth in sales of EGRIFTA SV formulation. com. (THTX) stock. Cookies are used to offer you a better browsing experience and to analyze our traffic. 9% more than in 2021. (TSX: TH) announced today that the Supreme Court of Canada has granted its appeal and dismissed 121851 Canada Inc. Stockhouse. 6. Stockhouse. FAQ – Émetteurs inscrits NOUVEAU. In collaboration with the University of Manitoba (UM), the company demonstrated that its photodynamic compound (PDC),. By continuing to use our service, you agree to our use of cookies. Second quarter 2022 earnings: Revenues miss analyst expectations Jul 15. Real-time Price Updates for Theratechnologies (TH-T), along with buy or sell indicators, analysis, charts, historical performance, news and more(2018-03-06 | TSX:TH) Theratechnologies Announces FDA Approval of Breakthrough Therapy, Trogarzo™ (ibalizumab-uiyk) Injection, the First HIV-1 Inhibitor and Long-Acting Monoclonal Antibody for Multidrug Resistant HIV-1. Consensus forecasts updated Jul 21. On average, they expect the company's stock price to reach $36. - Issued and outstanding common shares to be consolidated on the basis of 1 post. znewcar1. This news release constitutes a "designated news release" for the purposes of. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023. It's a different kind of fat that may require a different type of treatment. These pharmaceuticals. Microsoft (NDAQ:MSFT) will expand its presence in Quebec with new computing capacity and AI and. Theratechnologies Inc. TO) Stock Price, News, Quote & History - Yahoo Finance Canada Markets close in 43 mins S&P/TSX 20,125. com uses cookies on this site. European Headquarters. Cookies are used to offer you a better browsing experience and to analyze our traffic. MONTREAL, Aug. We also use them to share. 39 50-Day Range $0. 12, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies’ R&D staff is bearing the brunt of. MONTREAL, June 30, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. com uses cookies on this site. was a. - Issued and outstanding common shares to be consolidated on the basis of 1 post-consolidation share for each 4 pre-consolidation shares issued and outstanding, to regain compliance with NASDAQ listing requirements. Lead drug EGRIFTA (tesamorelin for injection) is being marketed for the reduction of excess abdominal fat in HIV-infected patients with. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 ir@theratech. Senior Director, Investor Relations. European Headquarters. (“Theratechnologies”, the “Company”, or “we”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has completed the previously announced consolidation of the issued. During the last trading day the stock fluctuated 4. We also use them to share usage. L. Get the latest Sernova Corp (SVA) real. View recently published Stock News reports from independent reports and journalists. Cookies are used to offer you a better browsing experience and to analyze our traffic. Montréal, Québec, Canada . Theratechnologies to Present at the Credit Suisse 30th Annual Healthcare Conference on November 11, 2021 Globe Newswire - Wed Nov 3, 2021 . Theratechnologies Stock Price, News and Company Updates. First Quarter Fiscal 2022 Financial Results. 28, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies Inc. MONTREAL, Feb. Type: Company - Public (TH) Revenue: $5 to $25 million (USD) Biotech & Pharmaceuticals. Background: Breast and ovarian cancer stem cells (CSC) can contribute to the invasive and chemoresistance phenotype of tumors. FY2023 revenue guidance range set between $90 million and $95 million. 49) by $0. 25, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. . Stockhouse. TH1902, a newly developed sortilin (SORT1)-targeted peptide-docetaxel conjugate is currently in phase-1 clinical trial. MONTREAL, Jan. Find the latest Theratechnologies Inc. This enduring webinar with Drs Arsalan Shah, Sarah Rowan, Stacey Trooskin, and Juliana Wallace will provide critical updates on specific strategies to improve testing and linkage to care, retention in care, and an overview of guidelines for treatment of HIV and HCV. WELCOME TO SEDAR+ File, disclose and search for issuer information in Canada’s capital markets Search SEDAR+ All public disclosure documents Reporting Issuers List Filing organizations from all jurisdictions Disciplined List People and companies under disciplinary action Cease Trade Orders People and companies restricted from trading securities Sign. “This is yet another major achievement for our oncology program. Biopharma Theratechnologies (NASDAQ:THTX) Friday announced that a study evaluating an intramuscular (IM) method of administration for its therapy, Trogarzo, did not meet the primary endpoint. Stockhouse. MONTREAL, May 25, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com uses cookies on this site. com uses cookies on this site. Trogarzo is a CD4-directed post-attachment HIV-1 inhibitor. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) ), a biopharmaceutical company focused on the development. Share your ideas and get valuable insights from the community of like minded traders and investors Headquarters. 60%. com uses cookies on this site. Stockhouse. We also use them to share usage information with our partners. D. L. com. We currently market prescription products for people with HIV in the United States. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. It is highly expressed in cancer cells compared to healthy tissue, which makes SORT1 an. org. /NOT FOR DISTRIBUTION TO UNITED STATES OF AMERICA WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES OF AMERICA/. TH1902 combines Theratechnologies’ proprietary peptide to docetaxel. It’s lead investigational peptide drug conjugate linked to docetaxel, a well-established and well-characterized cytotoxic agent used in the treatment of. com uses cookies on this site. We also use them to share usage. 65 per cent to C$1. TORONTO, Sept. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 4 million. . Investor Relations. com. (2022-10-26 | TSX:TH) Theratechnologies Reports Data Showing High Expression of Sortilin (SORT1) in Multiple Solid Tumors from Tissue Microarrays Stockhouse. The webinar will also address system-level barriers and present real-world. According to 3 analysts, the average rating for THTX stock is "Buy. (“Theratechnologies” or the “Company”) (TSX: TH) today announced that it has applied to list its common shares on NASDAQ. GlobeNewswire. T. com. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2023 financial results on Thursday, November 9, 2023 prior to market opening. T. MONTREAL, April 14, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies announced today that it will report its financial results for the second quarter of fiscal 2021 ended May 31, 2021 on. Theratechnologies Inc. Theratechnologies reduces R&D head count to compensate for sales setback. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced publi. 49%) At close: 04:00PM EST 1. Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies Inc. Data Link's cloud-based technology platform allows you to search, discover and access data and analytics for seamless integration via cloud APIs. Presented in part at the XVI International AIDS Conference; August 13–18, 2006; Toronto, Canada (abstracts TUP30058 AND THLB0218). (2023-07-21 | TSX:TH) Theratechnologies Announces the Resignation of One of Its Directors, Mr. Theratechnologies Unveils New Positive Data for Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Cancers. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis. 02%. TH | July 20, 2023. Marsolais’ presentation will be available through. Shares of Theratechnologies are up 4. Herein, we report. T. 03, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. S. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced receipt of the 2023 Industrial Research Sectoral Group (RSRI) Innovation Award from the CQDM (for. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has decided to pause the enrollment of patients in its Phase 1 clinical trial of. C. Company Participants. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its third quarter of fiscal 2022 ended August 31, on Thursday, October 13. com uses cookies on this site. NCU. The Notes were issued under a trust indenture dated as of June 19, 2018, by and among Theratechnologies and Computershare Trust Company of Canada. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. Phone Number 15143319691. com uses cookies on this site. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. Once expert advice is considered, the Company. Theratechnologies Inc. Competitors: Unknown. This news release constitutes a “designated news release” for the purposes of the Company’s. We also use them to share usage. One reason for that is that this tier does not include penny stocks. By continuing to use our service, you agree to our use of cookies. 65 per cent to C$1. View real-time stock prices and stock quotes for a full financial overview. The website address for Stockhouse has changed We changed the address of the Stockhouse website from to stockhouse. 28 $1. Their average twelve-month price target is $36. Stockhouse. com uses cookies on this site. Heures de négociation. Theratechnologies inc. Theratechnologies Inc. Investor Relations. Watch list NEW Set a price target alert After Hours Last. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 3089 Background: SORT1 is expressed in a variety of tumors when compared to most healthy tissue. We also use them to share usage. 35 as of 10:41 a. Cookies are used to offer you a better browsing experience and to. SORT1 is a “scavenger” receptor that plays a significant role in protein internalization, sorting, and. By continuing to use our service, you agree to our use of cookies. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691 Theratechnologies Announces Amendment to its Term Loan Facility With Affiliates of Marathon Asset Management. By continuing to use our service, you agree to our use of cookies. GUD | Complete Knight Therapeutics Inc. " The 12-month stock price forecast is $18. Theratechnologies Inc. Trogarzo ® is a long-acting, CD4-directed, post-attachment HIV-1 inhibitor. Investor Relations. OTCQX – this is the premium tier of OTC stocks. 08 (+6. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic. (2023-07-21 | TSX:TH) Theratechnologies Announces the Resignation of One of Its Directors, Mr. Theratechnologies Inc. FY2023 revenue guidance range set between $90 million and $95 million. Find more information. Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the second quarter and first half of. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ¨ Form 40-F xMain number: 514-336-7800. Losses were -47. 68 to a day high of $1. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (NASDAQ:NASDAQ:THTX) Q3 2022 Earnings Conference Call October 13, 2022 8:30 AM ETCompany ParticipantsElif McDonald - Head of Investor RelationsPaul Levesque -. Q4 2022 consolidated revenue growth of 14. (TSX-V: TLT, Forum) has demonstrated proof-of-concept for its Canadian-made COVID-19 vaccine. com uses cookies on this site. (2022-09-12 | TSX:TH) Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Fri, 17 Apr 2015 15:08:33 GMT ~ Supreme Court of Canada rules in favour of Theratechnologies. ET. Stockhouse. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business. (2015-07-23 | TSX:TH) Theratechnologies Announces $9,600,000 Firm Offering of Units and Filing of Preliminary Short Form Prospectus. TH | February 28, 2023. Selected news for Normal, Illinois and Cancer Therapy, which are filed under Locations / US Cities and Healthcare Topics, respectively. 00%. 40%. MONTREAL, Oct. 5%. Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented preclinical data that demonstrate the potential utility of its lead investigational. The company develops treatments for lipodystrophy . [at noodls] - Montreal, Canada - April 17, 2015 - Theratechnologies Inc. 17% from a day low at $1. Vancouver, Canada –– TheNewswire - April 7, 2022 - Teuton Resources Corp. July 24 - Heron Therapeutics: Heron is turning to layoffs for the second time in 13 months to cut. 33 +0. 521. By continuing to use our service, you agree to our use of cookies. FY2023 Revenue Guidance Range Confirmed Between $90 million and $95 million; Growth of the Commercial Portfolio in the Range of 13% and 19%. By continuing to use our service, you agree to our use of cookies. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Stockhouse. is an employee of TaiMed Biologics USA, Inc. 5% workforce reduction. Theratechnologies Announces 1-for-4 Reverse Stock Split. (2022-10-03 | TSX:TH) Theratechnologies' Trogarzo® Approved by FDA for 30-Second Intravenous (IV) Push, Simplifying HIV Treatment for Heavily Treatment-Experienced Population. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report financial results and provide a business update for its second. 86 million for the quarter. m. MONTREAL, Dec. ) Clinical-stage pharmaceutical company Theralase Technologies Inc. Montréal, Québec, Canada . Following the release, Knight will hold a conference call and audio webcast. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. The company’s previously announced offering was conducted by a syndicate of underwriters, including companies such as Canaccord Genuity. 10% least volatile stocks in CA Market. MONTREAL, Jan. Jours fériés des marchés. , a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. com uses cookies on this site. 617-356-1009. THERATECHNOLOGIES INC. Cookies are used to offer you a better browsing experience and to analyze our traffic. Headquarters. For investor inquiries: Leah Gibson. MONTREAL, March 29, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 03) EPS for the quarter, beating the consensus estimate of ($0. 11/05/2020 4:15:02 PM. GUD | Complete Knight Therapeutics Inc. Stockhouse. We currently market prescription products for people with HIV in the United States. (TH. We currently market prescription products for people with. For investor inquiries: Leah Gibson. T. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. Image source: The Motley Fool. MONTREAL, Jan. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Cookies are used to offer you a better browsing experience and to analyze our traffic. com uses cookies on this site. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 ir@theratech. 06 million, an increase of. FY2022 revenue. com. Theratechnologies Announces Fiscal Year 2023 Guidance and Operating Plan’s Key Objectives. Stockhouse. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. We currently market prescription products for people with HIV in the United States. (TH. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. MONTREAL, July 23, 2021 /CNW Telbec/ - Theratechnologies Inc. THERATECHNOLOGIES INC. Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors Stockhouse. Amount of cash a business has after it has met its financial obligations such as debt and outstanding payments. Theratechnologies is currently developing a platform of proprietary peptides called SORT1+ Technology TM for cancer drug development targeting SORT1 receptors. View real-time stock prices and stock quotes for a full financial overview. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that President and CEO, Paul Lévesque has issued an open letter to shareholders. Stockhouse. It is the Company’s proprietary peptide linked to docetaxel – a commonly used cytotoxic agent used to treat many cancers. com uses cookies on this site. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a commercial-stage biopharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical. 4%. com uses cookies on this site. [email protected] Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update T. MONTREAL, March 31, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Statut du système de négociation. MONTREAL, June 22, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies announced today that it will report its financial results for the second quarter of fiscal 2021 ended May 31, 2021 on Wednesday. 2% per year. Christian Marsolais, Ph. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company will present data from tissue microarrays showing high expression of. The company offers EGRIFTA and EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus. By continuing to use our service, you agree to our use of cookies. The company had revenue of $20. Theratechnologies Reports Financial Results and Business Updates for the Fourth Quarter and Full Year Fiscal 2022. Gary Littlejohn. 25. lgibson. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . com uses cookies on this site. In 2022, THTX's revenue was 80. 04, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. MONTREAL, Aug. com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. US Headquarters. MONTREAL, Oct. 9 million as at August 31, 2023. By continuing to use our service, you agree to our use of cookies. 22, 2023 /CNW/ - Northwest Healthcare Properties Real Estate Investment Trust (the "REIT" or "Northwest") (TSX: NWH. The company was. Theratechnologies inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. TORONTO, May 19, 2023. It is the Company’s proprietary. MONTREAL, April 08, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. MONTREAL, July 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. On July 28, 2023, Theratechnologies announced that the Company had entered into an agreement with certain funds and accounts for which Marathon Asset Management, L. MONTREAL, Sept. - 2023 Q3 positive adjusted EBITDA to be. com uses cookies on this site. (2020-03-31 | tsx:th) theratechnologies provides business update related to current covid-19 situation Stockhouse.